They excised Kdm6a exon 3 utilizing Mx1-cre transgenic mice and pIpC administration, similar to that of Gozdecka et al. However, this study followed the mice for only 4–5 months post-pIpC treatment, and did not describe the development of any malignancies. This evidence concerns the gene KDM6A and cancer.